vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and NACCO INDUSTRIES INC (NC). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $66.8M, roughly 1.3× NACCO INDUSTRIES INC). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -5.2%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 11.9%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
NACCO Industries, Inc. is an American publicly traded holding company, headquartered in Cleveland, Ohio. Through a portfolio of mining and natural resources businesses, the company operates under three business segments: Coal Mining, North American Mining, and Minerals Management. The Coal Mining segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The North American Mining se...
IOVA vs NC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $66.8M |
| Net Profit | — | $-3.8M |
| Gross Margin | 67.4% | 18.0% |
| Operating Margin | -84.7% | 11.3% |
| Net Margin | — | -5.8% |
| Revenue YoY | 17.7% | -5.2% |
| Net Profit YoY | — | -150.8% |
| EPS (diluted) | — | $-0.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $66.8M | ||
| Q3 25 | $67.5M | $76.6M | ||
| Q2 25 | $60.0M | $68.2M | ||
| Q1 25 | $49.3M | $65.6M | ||
| Q4 24 | $73.7M | $70.4M | ||
| Q3 24 | $58.6M | $61.7M | ||
| Q2 24 | $31.1M | $52.3M | ||
| Q1 24 | $715.0K | $53.3M |
| Q4 25 | — | $-3.8M | ||
| Q3 25 | $-91.3M | $13.3M | ||
| Q2 25 | $-111.7M | $3.3M | ||
| Q1 25 | $-116.2M | $4.9M | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $-83.5M | $15.6M | ||
| Q2 24 | $-97.1M | $6.0M | ||
| Q1 24 | $-113.0M | $4.6M |
| Q4 25 | 67.4% | 18.0% | ||
| Q3 25 | 43.0% | 13.0% | ||
| Q2 25 | 5.5% | 10.0% | ||
| Q1 25 | -0.8% | 14.7% | ||
| Q4 24 | 68.7% | 12.0% | ||
| Q3 24 | 46.2% | 11.7% | ||
| Q2 24 | -0.8% | 13.4% | ||
| Q1 24 | — | 13.2% |
| Q4 25 | -84.7% | 11.3% | ||
| Q3 25 | -140.7% | 8.8% | ||
| Q2 25 | -189.8% | -0.1% | ||
| Q1 25 | -245.8% | 11.7% | ||
| Q4 24 | -117.5% | 5.5% | ||
| Q3 24 | -152.1% | 31.9% | ||
| Q2 24 | -327.6% | 14.1% | ||
| Q1 24 | -16464.6% | 8.9% |
| Q4 25 | — | -5.8% | ||
| Q3 25 | -135.3% | 17.3% | ||
| Q2 25 | -186.2% | 4.8% | ||
| Q1 25 | -235.5% | 7.5% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | -142.7% | 25.4% | ||
| Q2 24 | -312.2% | 11.4% | ||
| Q1 24 | -15800.8% | 8.6% |
| Q4 25 | — | $-0.53 | ||
| Q3 25 | — | $1.78 | ||
| Q2 25 | $-0.33 | $0.44 | ||
| Q1 25 | $-0.36 | $0.66 | ||
| Q4 24 | $-0.24 | $0.99 | ||
| Q3 24 | $-0.28 | $2.14 | ||
| Q2 24 | $-0.34 | $0.81 | ||
| Q1 24 | $-0.42 | $0.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $49.7M |
| Total DebtLower is stronger | — | $100.8M |
| Stockholders' EquityBook value | $698.6M | $429.2M |
| Total Assets | $913.2M | $661.2M |
| Debt / EquityLower = less leverage | — | 0.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $49.7M | ||
| Q3 25 | $300.8M | $52.7M | ||
| Q2 25 | $301.2M | $49.4M | ||
| Q1 25 | $359.7M | $61.9M | ||
| Q4 24 | $323.8M | $72.8M | ||
| Q3 24 | $397.5M | $63.1M | ||
| Q2 24 | $412.5M | $62.4M | ||
| Q1 24 | $356.2M | $61.8M |
| Q4 25 | — | $100.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $99.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $29.0M | ||
| Q1 24 | — | $28.4M |
| Q4 25 | $698.6M | $429.2M | ||
| Q3 25 | $702.3M | $426.4M | ||
| Q2 25 | $698.5M | $413.1M | ||
| Q1 25 | $767.9M | $409.1M | ||
| Q4 24 | $710.4M | $404.9M | ||
| Q3 24 | $773.5M | $397.3M | ||
| Q2 24 | $768.5M | $384.1M | ||
| Q1 24 | $680.0M | $381.6M |
| Q4 25 | $913.2M | $661.2M | ||
| Q3 25 | $904.9M | $637.6M | ||
| Q2 25 | $907.4M | $631.3M | ||
| Q1 25 | $966.7M | $634.2M | ||
| Q4 24 | $910.4M | $631.7M | ||
| Q3 24 | $991.1M | $597.4M | ||
| Q2 24 | $964.3M | $560.1M | ||
| Q1 24 | $869.8M | $538.0M |
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $11.4M |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $11.4M | ||
| Q3 25 | $-78.7M | $42.3M | ||
| Q2 25 | $-67.4M | $-7.8M | ||
| Q1 25 | $-103.7M | $5.0M | ||
| Q4 24 | $-73.3M | $25.2M | ||
| Q3 24 | $-59.0M | $2.8M | ||
| Q2 24 | $-98.4M | $4.1M | ||
| Q1 24 | $-122.3M | $-9.8M |
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-89.5M | — | ||
| Q2 25 | $-74.9M | — | ||
| Q1 25 | $-109.9M | — | ||
| Q4 24 | $-77.5M | — | ||
| Q3 24 | $-61.3M | — | ||
| Q2 24 | $-98.9M | — | ||
| Q1 24 | $-126.5M | — |
| Q4 25 | -71.3% | — | ||
| Q3 25 | -132.7% | — | ||
| Q2 25 | -124.9% | — | ||
| Q1 25 | -222.8% | — | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -104.6% | — | ||
| Q2 24 | -317.9% | — | ||
| Q1 24 | -17685.3% | — |
| Q4 25 | 10.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 583.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.19× | ||
| Q2 25 | — | -2.39× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 3.33× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.68× | ||
| Q1 24 | — | -2.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
NC
| Transferred Over Time | $42.7M | 64% |
| Transferred At Point In Time | $24.1M | 36% |
